Selective modulation of follicle-stimulating hormone signaling pathways with enhancing equine chorionic gonadotropin/antibody immune complexes

Endocrinology

Volumn 151, Issue 6, 2010, Pages 2788-2799

  Wehbi, Vanessa ^a   Decourtye, Jérémy ^a   Piketty, Vincent ^a   Durand, Guillaume ^a   Reiter, Eric ^a   Maurel, Marie Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; CHORIONIC GONADOTROPIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; EQUINE CHORIONIC GONADOTROPIN; FOLLITROPIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTIBODY; BETA ARRESTIN; CYCLIC AMP; ISOQUINOLINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; RETINA S ANTIGEN; SERIC GONADOTROPIN; SULFONAMIDE;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BIOLOGICAL ACTIVITY; CELL STRAIN HEK293; CONTROLLED STUDY; FEMALE; FERTILITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC TRANSFECTION; HORMONAL REGULATION; HORMONE ACTION; IMMUNOMODULATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TARGET CELL; CELL LINE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; KINETICS; METABOLISM; PHOSPHORYLATION;

ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; ARRESTINS; CELL LINE; CHORIONIC GONADOTROPIN; CYCLIC AMP; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FOLLICLE STIMULATING HORMONE; GONADOTROPINS, EQUINE; HUMANS; ISOQUINOLINES; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 77954473787     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0892     Document Type: Article

References (56)

1. Allen WR, Moor RM 1972 The origin of the equine endometrial cups. I. Production of PMSG by fetal trophoblast cells. J Reprod Fertil 29:313-316
2. Papkoff H 1974 Chemical and biological properties of the subunits of pregnant mare serum gonadotropin. Biochem Biophys Res Commun 58:397-404
3. Christakos S, Bahl OP 1979 Pregnant mare serum gonadotropin. Purification and physicochemical, biological, and immunological characterization. J Biol Chem 254:4253-4261
4. Catchpole HR, Cole HH, Pearson PB 1935 Studies on the rate of disapearance and fate of mare gonadotropic hormone following intravenous injection. Am J Physiol 112:21-26
5. McIntosh JE, Moor RM, Allen WR 1975 Pregnant mare serum gonadotrophin: rate of clearance from the circulation of sheep. J Reprod Fertil 44:95-100
6. Matzuk MM, Hsueh AJ, Lapolt P, Tsafriri A, Keene JL, Boime I 1990 The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] β-subunit. Endocrinology 126:376-383
7. Guillou F, Combarnous Y 1983 Purification of equine gonadotropins and comparative study of their acid-dissociation and receptor-binding specificity. Biochim Biophys Acta 755:229-236
8. Combarnous Y, Guillou F, Martinat N 1984 Comparison of in vitro follicle-stimulating hormone (FSH) activity of equine gonadotropins (luteinizing hormone, FSH, and chorionic gonadotropin) in male and female rats. Endocrinology 115:1821-1827
9. Combarnous Y, Hennen G, Ketelslegers JM 1978 Pregnant mare serum gonadotropin exhibits higher affinity for lutropin than for follitropin receptors of porcine testis. FEBS Lett 90:65-68
10. Licht P, Gallo AB, Aggarwal BB, Farmer SW, Castelino JB, Papkoff H 1979 Biological and binding activities of equine pituitary gonadotrophins and pregnant mare serum gonadotrophin. J Endocrinol 83:311-322
11. Roy F, Combes B, Vaiman D, Cribiu EP, Pobel T, Delétang F, Combarnous Y, Guillou F, Maurel MC 1999 Humoral immune response to equine chorionic gonadotropin in ewes: association with major histocompatibility complex and interference with subsequent fertility. Biol Reprod 61:209-218 (Pubitemid 29295987)
12. Roy F, Maurel MC, Combes B, Vaiman D, Cribiu EP, Lantier I, Pobel T, Delétang F, Combarnous Y, Guillou F 1999 The negative effect of repeated equine chorionic gonadotropin treatment on subsequent fertility in Alpine goats is due to a humoralimmuneresponse involving the major histocompatibility complex. Biol Reprod 60:805-813
13. Guillou F, Martinat N, Combarnous Y 1985 Rapid in vitro desensitization of the testosterone response in rat Leydig cells by subactive concentrations of porcine luteinizing hormone. FEBS Lett 184:6-9
14. Kelton CA, Cheng SV, Nugent NP, Schweickhardt RL, Rosenthal JL, Overton SA, Wands GD, Kuzeja JB, Luchette CA, Chappel SC 1992 The cloning of the human follicle stimulating hormone receptor and its expression in COS-7, CHO, and Y-1 cells. Mol Cell Endocrinol 89:141-151
15. Hervé V, Roy F, Bertin J, Guillou F, Maurel MC 2004 Antiequine chorionic gonadotropin (eCG) antibodies generated in goats treated with eCG for the induction of ovulation modulate the luteinizing hormone and follicle-stimulating hormone bioactivities of eCG differently. Endocrinology 145:294-303
16. Ferasin L, Gabai G, Beattie J, Bono G, Holder AT 1997 Enhancement of FSH bioactivity in vivo using site-specific antisera. J Endocrinol 152:355-363
17. Glencross RG, Lovell RD, Holder AT 1993 Monoclonal antibody enhancement of FSH-induced uterine growth in snell dwarf mice. J Endocrinol 136:R5-R7
18. Holder AT, Aston R, Preece MA, Ivanyi J 1985 Monoclonal antibody-mediated enhancement of growth hormone activity in vivo. J Endocrinol 107:R9-R12
19. Xie YB, Wang H, Segaloff DL 1990 Extracellular domain of lutropin/choriogonadotropin receptor expressed in transfected cells binds choriogonadotropin with high affinity. J Biol Chem 265:21411-21414
20. Holder AT, Aston R, Rest JR, Hill DJ, Patel N, Ivanyi J 1987 Monoclonal antibodies can enhance the biological activity of thyrotropin. Endocrinology 120:567-573
21. Aston R, Holder AT, Ivanyi J, Bomford R 1987 Enhancement of bovine growth hormone activity in vivo by monoclonal antibodies. Mol Immunol 24:143-150
22. Pell JM, Johnsson ID, Pullar RA, Morrell DJ, Hart IC, Holder AT, Aston R 1989 Potentiation of growth hormone activity in sheep using monoclonal antibodies. J Endocrinol 120:R15-R18
23. Boyman O, Surh CD, Sprent J 2006 Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 6:1323-1331
24. Boyman O, Ramsey C, Kim DM, Sprent J, Surh CD 2008 IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 180:7265-7275
25. Kara E, Crépieux P, Gauthier C, Martinat N, Piketty V, Guillou F, Reiter E 2006 Aphosphorylation cluster of five serine and threonine residues in the C-terminus of the follicle-stimulating hormone receptor is important for desensitization but not for β-arrestin-mediated ERK activation. Mol Endocrinol 20:3014-3026
26. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ 2008 β-Arrestin-biased agonism at the β 2-adrenergic receptor. J Biol Chem 283:5669-5676
27. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Piñeyro G 2003 β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411
28. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, Luttrell LM, Lefkowitz RJ 2006 Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864
29. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ 2003 Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787
30. Morshed SA, Latif R, Davies TF 2009 Characterization of Tsh receptor antibody induced signaling cascades. Endocrinology 150:519-529
31. Kenakin T 2007 Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72:1393-1401
32. Violin JD, Lefkowitz RJ 2007 β-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28:416-422
33. Chopineau M, Maurel MC, Combarnous Y, Durand P 1993 Topography of equine chorionic gonadotropin epitopes relative to the luteinizing hormone and follicle-stimulating hormone receptor interaction sites. Mol Cell Endocrinol 92:229-239
34. Tosca L, Froment P, Solnais P, Ferré P, Foufelle F, Dupont J 2005 Adenosine 5′-monophosphate-activated protein kinase regulates progesterone secretion in rat granulosa cells. Endocrinology 146:4500-4513
35. DiPilato LM, Cheng X, Zhang J 2004 Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc Natl Acad Sci USA 101:16513-16518
36. Zhang J, Ma Y, Taylor SS, Tsien RY 2001 Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering. Proc Natl Acad Sci USA 98:14997-15002
37. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ 2003 Desensitization, internalization, and signaling functions of β-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 100:1740-1744
38. Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ 2005 Different G protein-coupled receptor kinases govern G protein and β-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci USA 102:1448-1453 (Pubitemid 40209190)
39. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, Lefkowitz RJ 2005 Functional antagonism of different G protein-coupled receptor kinases for β-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci USA 102:1442-1447 (Pubitemid 40209189)
40. Crépieux P, Marion S, Martinat N, Fafeur V, Vern YL, Kerboeuf D, Guillou F, Reiter E 2001 The ERK-dependent signaling is stage-specifically modulated by FSH, during primary Sertoli cell maturation. Oncogene 20:4696-4709
41. Dewi DA, Abayasekara DR, Wheeler-Jones CP 2002 Requirement for ERK1/2 activation in the regulation of progesterone production in human granulosa-lutein cells is stimulus specific. Endocrinology 143:877-888
42. Barthet G, Gaven F, Framery B, Shinjo K, Nakamura T, Claeysen S, Bockaert J, Dumuis A 2005 Uncoupling and endocytosis of 5-hydroxytryptamine 4 receptors. J Biol Chem 280:27924-27934
43. Kenakin T 2001 Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611
44. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, Caron MG 2008 Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105:13656-13661
45. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ 2007 A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA 104:16657-16662
46. Neubig RR 2007 Missing links: mechanisms of protean agonism. Mol Pharmacol 71:1200-1202
47. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB 2007 Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13
48. Vauquelin G, Van Liefde I 2005 G protein-coupled receptors: a count of 1001 conformations. Fundam Clin Pharmacol 19:45-56
49. Kenakin T 1995 Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238
50. Arey BJ, Stevis PE, Deecher DC, Shen ES, Frail DE, Negro-Vilar A, Lopez FJ 1997 Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms. Mol Endocrinol 11:517-526
51. Arey BJ, Yanofsky SD, Claudia Pérez M, Holmes CP, Wrobel J, Gopalsamy A, Stevis PE, López FJ, Winneker RC 2008 Differing pharmacological activities of thiazolidinone analogs at the FSH receptor. Biochem Biophys Res Commun 368:723-728
52. Sanders J, Bolton J, Sanders P, Jeffreys J, Nakatake N, Richards T, Evans M, Kiddie A, Summerhayes S, Roberts E, Miguel RN, Furmaniak J, Smith BR 2006 Effects of TSH receptor mutations on binding and biological activity of monoclonal antibodies and TSH. Thyroid 16:1195-1206
53. Galandrin S, Bouvier M 2006 Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584
54. Galandrin S, Oligny-Longpré G, Bouvier M 2007 The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430
55. Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, Monteillet-Agius G, Stewart PL, Evans CJ, von Zastrow M 1998 μ-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53:377-384
56. Bhowmick N, Narayan P, Puett D 1998 The endothelin subtype A receptor undergoes agonist- and antagonist-mediated internalization in the absence of signaling. Endocrinology 139:3185-3192